Nature Communications (Sep 2017)

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

  • Sathana Dushyanthen,
  • Zhi Ling Teo,
  • Franco Caramia,
  • Peter Savas,
  • Christopher P. Mintoff,
  • Balaji Virassamy,
  • Melissa A. Henderson,
  • Stephen J. Luen,
  • Mariam Mansour,
  • Michael H. Kershaw,
  • Joseph A. Trapani,
  • Paul J. Neeson,
  • Roberto Salgado,
  • Grant A. McArthur,
  • Justin M. Balko,
  • Paul A. Beavis,
  • Phillip K. Darcy,
  • Sherene Loi

DOI
https://doi.org/10.1038/s41467-017-00728-9
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 18

Abstract

Read online

MEK inhibition in breast cancer is associated with increased tumour infiltrating lymphocytes (TILs), however, MAPK activity is required for T cells function. Here the authors show that TILs activity following MEK inhibition can be enhanced by agonist immunotherapy resulting in synergic therapeutic effects.